Taipei Exchange - Delayed Quote TWD

Genovate Biotechnology Co., Ltd. (4130.TWO)

Compare
21.15 +0.45 (+2.17%)
At close: 1:30:35 PM GMT+8
Loading Chart for 4130.TWO
DELL
  • Previous Close 20.70
  • Open 20.90
  • Bid --
  • Ask --
  • Day's Range 20.90 - 21.25
  • 52 Week Range 20.39 - 26.31
  • Volume 122,657
  • Avg. Volume 93,502
  • Market Cap (intraday) 2.359B
  • Beta (5Y Monthly) 0.13
  • PE Ratio (TTM) 151.07
  • EPS (TTM) 0.14
  • Earnings Date --
  • Forward Dividend & Yield 0.15 (0.69%)
  • Ex-Dividend Date Aug 21, 2024
  • 1y Target Est --

Genovate Biotechnology Co., Ltd. operates as a specialty pharmaceutical company in Taiwan. It offers central nervous system drugs, cardiovascular drugs, musculoskeletal drugs, immune preparation drugs, anti-infective agents, anticancer drugs, anti-viral drugs, respiratory drugs, genitourinary drugs, and gastrointestinal drugs. The company manufactures active pharmaceutical ingredients, intermediates, controlled release medicine, and cosmetic products. Genovate Biotechnology Co., Ltd. was founded in 1982 and is based in Hsinchu City, Taiwan.

www.genovate-bio.com

194

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 4130.TWO

View More

Performance Overview: 4130.TWO

Trailing total returns as of 12/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

4130.TWO
17.56%
TSEC CAPITALIZATION WEIGHTED ST
29.65%

1-Year Return

4130.TWO
17.09%
TSEC CAPITALIZATION WEIGHTED ST
32.05%

3-Year Return

4130.TWO
11.44%
TSEC CAPITALIZATION WEIGHTED ST
29.43%

5-Year Return

4130.TWO
5.56%
TSEC CAPITALIZATION WEIGHTED ST
93.59%

Compare To: 4130.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 4130.TWO

View More

Valuation Measures

As of 12/25/2024
  • Market Cap

    2.31B

  • Enterprise Value

    1.79B

  • Trailing P/E

    145.64

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.56

  • Price/Book (mrq)

    1.56

  • Enterprise Value/Revenue

    3.49

  • Enterprise Value/EBITDA

    30.38

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    5.22%

  • Return on Assets (ttm)

    1.03%

  • Return on Equity (ttm)

    1.83%

  • Revenue (ttm)

    522.76M

  • Net Income Avi to Common (ttm)

    27.3M

  • Diluted EPS (ttm)

    0.14

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    538.6M

  • Total Debt/Equity (mrq)

    0.20%

  • Levered Free Cash Flow (ttm)

    48.44M

Research Analysis: 4130.TWO

View More

People Also Watch